Alefacept
- Generic Name
- Alefacept
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 222535-22-0
- Unique Ingredient Identifier
- ELK3V90G6C
- Background
Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD.
- Indication
As an immunosuppressive drug, Alefacept can be used for treatment of moderate to severe chronic plaque psoriasis
- Associated Conditions
- -
- Associated Therapies
- -
A Placebo-controlled Study With an Extension Examining the Safety and Efficacy of Alefacept in Psoriatic Arthritis
- Conditions
- Interventions
- First Posted Date
- 2008-04-16
- Last Posted Date
- 2014-09-18
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 185
- Registration Number
- NCT00659412
Assess the Efficacy and Safety of Alefacept With Narrow Band Ultraviolet B Phototherapy (nbUVB) vs. Alefacept Alone in Chronic Plaque Psoriasis Subjects
- Conditions
- Interventions
- First Posted Date
- 2008-04-15
- Last Posted Date
- 2013-01-08
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 98
- Registration Number
- NCT00658606
Long-Term One Year Use of Alefacept (Amevive®) in Moderate to Severe Chronic Plaque Type Psoriasis
- First Posted Date
- 2008-04-10
- Last Posted Date
- 2018-09-11
- Lead Sponsor
- Wake Forest University
- Target Recruit Count
- 15
- Registration Number
- NCT00655564
- Locations
- 🇺🇸
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
A Study of Pharmacokinetics and Safety of Alefacept in Caucasian and Japanese Healthy Volunteers
- First Posted Date
- 2008-04-07
- Last Posted Date
- 2013-02-28
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 75
- Registration Number
- NCT00653822
A Study to Assess the Efficacy and Safety of Alefacept in Kidney Transplant Recipients
- Conditions
- Interventions
- First Posted Date
- 2008-02-18
- Last Posted Date
- 2016-02-04
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 218
- Registration Number
- NCT00617604
A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients
- Conditions
- Interventions
- First Posted Date
- 2007-10-15
- Last Posted Date
- 2015-12-11
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 323
- Registration Number
- NCT00543569
- Locations
- 🇺🇸
University of North Carolina, Chapel Hill, North Carolina, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸Methodist University Hospital - Memphis, Memphis, Tennessee, United States
Study to Evaluate the Immune Response to Pneumococcal Vaccine in Alefacept-treated Adults With Chronic Plaque Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2007-06-28
- Last Posted Date
- 2012-02-02
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 43
- Registration Number
- NCT00493324
Alefacept in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma or Peripheral T-Cell Non-Hodgkin's Lymphoma
- First Posted Date
- 2007-02-22
- Last Posted Date
- 2019-08-13
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 23
- Registration Number
- NCT00438802
- Locations
- 🇺🇸
Mayo Clinic Cancer Center, Rochester, Minnesota, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸Holden Comprehensive Cancer Center at University of Iowa, Iowa City, Iowa, United States
Alefacept for Chronic Graft Versus Host Disease
- Conditions
- First Posted Date
- 2006-11-09
- Last Posted Date
- 2015-04-21
- Lead Sponsor
- Hadassah Medical Organization
- Target Recruit Count
- 20
- Registration Number
- NCT00397332
- Locations
- 🇮🇱
Department of Stem cell Transplantation & Cancer immunotherapy; Cell Therapy & Transplantation Biology Research Laboratory, Hadassah University Hospital, Jerusalem, Israel
Open-Label,Singel Center Study of Alefacept in Patients With Atopic Dermatitis
- First Posted Date
- 2006-09-14
- Last Posted Date
- 2007-12-10
- Lead Sponsor
- Insel Gruppe AG, University Hospital Bern
- Target Recruit Count
- 10
- Registration Number
- NCT00376129
- Locations
- 🇨🇭
Inselspital Dermatology, Bern, Switzerland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.